Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: Prognostic factors associated with clinical outcomes

Maartje G. Schouwenburg, Anouk Jochems, Brenda Leeneman, Margreet G. Franken, Alfons J. M. van den Eertwegh, John B. A. G. Haanen, Michiel C. T. van Zeijl, Maureen J. Aarts, Alexander C. J. van Akkooi, Franchette W. P. J. van den Berkmortel, Willeke A. M. Blokx, Jan Willem B. de Groot, Geke A. P. Hospers, Ellen Kapiteijn, Rutger H. Koornstra, Wim H. Kruit, Marieke W. J. Louwman, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk & 4 others Albert J. ten Tije, Gerard Vreugdenhil, Michel W. J. M. Wouters, Jacobus J. M. van der Hoeven

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The aim of this population-based study was to identify the factors associated with clinical outcomes in vemurafenib-Treated patients and to evaluate outcomes across subgroups of patients with different risk profiles. Data were retrieved from the Dutch Melanoma Treatment Registry. Time to next treatment (TTNT) and overall survival (OS) of all metastatic melanoma patients who received vemurafenib between 2012 and 2015 were assessed using Kaplan-Meier estimates. A risk score was developed on the basis of all prognostic factors associated with TTNT and OS derived from multivariable Cox regression analyses. Patients were stratified according to the presence of prognostic risk factors by counting the number of factors, ranging from 0 to 6. A total of 626 patients received vemurafenib with a median follow-up of 35.8 months. The median TTNT and OS were 4.7 months [95% confidence intervals (CI): 4.4-5.1] and 7.3 months (95% CI: 6.6-8.0). The strongest prognostic factors were serum lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group performance score, number of organ sites involved and brain metastases. Patients with a favourable risk profile (no risk factors) had a median TTNT and OS of 7.1 (95% CI: 5.8-8.5) and 15.4 months (95% CI: 10.0-20.9). The median OS more than halved for patients with greater than or equal to 2 risk factors compared with patients with no risk factors. The clinical outcomes of vemurafenib in metastatic melanoma patients with a favourable risk profile are comparable with the results of the trials. Combining prognostic factors into a risk score could be valuable to stratify patients into favourable and poor-prognosis groups.
Original languageEnglish
Pages (from-to)326-332
JournalMelanoma Research
Volume28
Issue number4
DOIs
Publication statusPublished - 2018

Cite this

Schouwenburg, Maartje G. ; Jochems, Anouk ; Leeneman, Brenda ; Franken, Margreet G. ; van den Eertwegh, Alfons J. M. ; Haanen, John B. A. G. ; van Zeijl, Michiel C. T. ; Aarts, Maureen J. ; van Akkooi, Alexander C. J. ; van den Berkmortel, Franchette W. P. J. ; Blokx, Willeke A. M. ; de Groot, Jan Willem B. ; Hospers, Geke A. P. ; Kapiteijn, Ellen ; Koornstra, Rutger H. ; Kruit, Wim H. ; Louwman, Marieke W. J. ; Piersma, Djura ; van Rijn, Rozemarijn S. ; Suijkerbuijk, Karijn P. M. ; ten Tije, Albert J. ; Vreugdenhil, Gerard ; Wouters, Michel W. J. M. ; van der Hoeven, Jacobus J. M. / Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: Prognostic factors associated with clinical outcomes. In: Melanoma Research. 2018 ; Vol. 28, No. 4. pp. 326-332.
@article{d31e97b3f52e4c9b80f9e0d4bbce7940,
title = "Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: Prognostic factors associated with clinical outcomes",
abstract = "The aim of this population-based study was to identify the factors associated with clinical outcomes in vemurafenib-Treated patients and to evaluate outcomes across subgroups of patients with different risk profiles. Data were retrieved from the Dutch Melanoma Treatment Registry. Time to next treatment (TTNT) and overall survival (OS) of all metastatic melanoma patients who received vemurafenib between 2012 and 2015 were assessed using Kaplan-Meier estimates. A risk score was developed on the basis of all prognostic factors associated with TTNT and OS derived from multivariable Cox regression analyses. Patients were stratified according to the presence of prognostic risk factors by counting the number of factors, ranging from 0 to 6. A total of 626 patients received vemurafenib with a median follow-up of 35.8 months. The median TTNT and OS were 4.7 months [95{\%} confidence intervals (CI): 4.4-5.1] and 7.3 months (95{\%} CI: 6.6-8.0). The strongest prognostic factors were serum lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group performance score, number of organ sites involved and brain metastases. Patients with a favourable risk profile (no risk factors) had a median TTNT and OS of 7.1 (95{\%} CI: 5.8-8.5) and 15.4 months (95{\%} CI: 10.0-20.9). The median OS more than halved for patients with greater than or equal to 2 risk factors compared with patients with no risk factors. The clinical outcomes of vemurafenib in metastatic melanoma patients with a favourable risk profile are comparable with the results of the trials. Combining prognostic factors into a risk score could be valuable to stratify patients into favourable and poor-prognosis groups.",
author = "Schouwenburg, {Maartje G.} and Anouk Jochems and Brenda Leeneman and Franken, {Margreet G.} and {van den Eertwegh}, {Alfons J. M.} and Haanen, {John B. A. G.} and {van Zeijl}, {Michiel C. T.} and Aarts, {Maureen J.} and {van Akkooi}, {Alexander C. J.} and {van den Berkmortel}, {Franchette W. P. J.} and Blokx, {Willeke A. M.} and {de Groot}, {Jan Willem B.} and Hospers, {Geke A. P.} and Ellen Kapiteijn and Koornstra, {Rutger H.} and Kruit, {Wim H.} and Louwman, {Marieke W. J.} and Djura Piersma and {van Rijn}, {Rozemarijn S.} and Suijkerbuijk, {Karijn P. M.} and {ten Tije}, {Albert J.} and Gerard Vreugdenhil and Wouters, {Michel W. J. M.} and {van der Hoeven}, {Jacobus J. M.}",
year = "2018",
doi = "10.1097/CMR.0000000000000453",
language = "English",
volume = "28",
pages = "326--332",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Schouwenburg, MG, Jochems, A, Leeneman, B, Franken, MG, van den Eertwegh, AJM, Haanen, JBAG, van Zeijl, MCT, Aarts, MJ, van Akkooi, ACJ, van den Berkmortel, FWPJ, Blokx, WAM, de Groot, JWB, Hospers, GAP, Kapiteijn, E, Koornstra, RH, Kruit, WH, Louwman, MWJ, Piersma, D, van Rijn, RS, Suijkerbuijk, KPM, ten Tije, AJ, Vreugdenhil, G, Wouters, MWJM & van der Hoeven, JJM 2018, 'Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: Prognostic factors associated with clinical outcomes' Melanoma Research, vol. 28, no. 4, pp. 326-332. https://doi.org/10.1097/CMR.0000000000000453

Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: Prognostic factors associated with clinical outcomes. / Schouwenburg, Maartje G.; Jochems, Anouk; Leeneman, Brenda; Franken, Margreet G.; van den Eertwegh, Alfons J. M.; Haanen, John B. A. G.; van Zeijl, Michiel C. T.; Aarts, Maureen J.; van Akkooi, Alexander C. J.; van den Berkmortel, Franchette W. P. J.; Blokx, Willeke A. M.; de Groot, Jan Willem B.; Hospers, Geke A. P.; Kapiteijn, Ellen; Koornstra, Rutger H.; Kruit, Wim H.; Louwman, Marieke W. J.; Piersma, Djura; van Rijn, Rozemarijn S.; Suijkerbuijk, Karijn P. M.; ten Tije, Albert J.; Vreugdenhil, Gerard; Wouters, Michel W. J. M.; van der Hoeven, Jacobus J. M.

In: Melanoma Research, Vol. 28, No. 4, 2018, p. 326-332.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: Prognostic factors associated with clinical outcomes

AU - Schouwenburg, Maartje G.

AU - Jochems, Anouk

AU - Leeneman, Brenda

AU - Franken, Margreet G.

AU - van den Eertwegh, Alfons J. M.

AU - Haanen, John B. A. G.

AU - van Zeijl, Michiel C. T.

AU - Aarts, Maureen J.

AU - van Akkooi, Alexander C. J.

AU - van den Berkmortel, Franchette W. P. J.

AU - Blokx, Willeke A. M.

AU - de Groot, Jan Willem B.

AU - Hospers, Geke A. P.

AU - Kapiteijn, Ellen

AU - Koornstra, Rutger H.

AU - Kruit, Wim H.

AU - Louwman, Marieke W. J.

AU - Piersma, Djura

AU - van Rijn, Rozemarijn S.

AU - Suijkerbuijk, Karijn P. M.

AU - ten Tije, Albert J.

AU - Vreugdenhil, Gerard

AU - Wouters, Michel W. J. M.

AU - van der Hoeven, Jacobus J. M.

PY - 2018

Y1 - 2018

N2 - The aim of this population-based study was to identify the factors associated with clinical outcomes in vemurafenib-Treated patients and to evaluate outcomes across subgroups of patients with different risk profiles. Data were retrieved from the Dutch Melanoma Treatment Registry. Time to next treatment (TTNT) and overall survival (OS) of all metastatic melanoma patients who received vemurafenib between 2012 and 2015 were assessed using Kaplan-Meier estimates. A risk score was developed on the basis of all prognostic factors associated with TTNT and OS derived from multivariable Cox regression analyses. Patients were stratified according to the presence of prognostic risk factors by counting the number of factors, ranging from 0 to 6. A total of 626 patients received vemurafenib with a median follow-up of 35.8 months. The median TTNT and OS were 4.7 months [95% confidence intervals (CI): 4.4-5.1] and 7.3 months (95% CI: 6.6-8.0). The strongest prognostic factors were serum lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group performance score, number of organ sites involved and brain metastases. Patients with a favourable risk profile (no risk factors) had a median TTNT and OS of 7.1 (95% CI: 5.8-8.5) and 15.4 months (95% CI: 10.0-20.9). The median OS more than halved for patients with greater than or equal to 2 risk factors compared with patients with no risk factors. The clinical outcomes of vemurafenib in metastatic melanoma patients with a favourable risk profile are comparable with the results of the trials. Combining prognostic factors into a risk score could be valuable to stratify patients into favourable and poor-prognosis groups.

AB - The aim of this population-based study was to identify the factors associated with clinical outcomes in vemurafenib-Treated patients and to evaluate outcomes across subgroups of patients with different risk profiles. Data were retrieved from the Dutch Melanoma Treatment Registry. Time to next treatment (TTNT) and overall survival (OS) of all metastatic melanoma patients who received vemurafenib between 2012 and 2015 were assessed using Kaplan-Meier estimates. A risk score was developed on the basis of all prognostic factors associated with TTNT and OS derived from multivariable Cox regression analyses. Patients were stratified according to the presence of prognostic risk factors by counting the number of factors, ranging from 0 to 6. A total of 626 patients received vemurafenib with a median follow-up of 35.8 months. The median TTNT and OS were 4.7 months [95% confidence intervals (CI): 4.4-5.1] and 7.3 months (95% CI: 6.6-8.0). The strongest prognostic factors were serum lactate dehydrogenase (LDH) level, Eastern Cooperative Oncology Group performance score, number of organ sites involved and brain metastases. Patients with a favourable risk profile (no risk factors) had a median TTNT and OS of 7.1 (95% CI: 5.8-8.5) and 15.4 months (95% CI: 10.0-20.9). The median OS more than halved for patients with greater than or equal to 2 risk factors compared with patients with no risk factors. The clinical outcomes of vemurafenib in metastatic melanoma patients with a favourable risk profile are comparable with the results of the trials. Combining prognostic factors into a risk score could be valuable to stratify patients into favourable and poor-prognosis groups.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85049615120&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29750749

U2 - 10.1097/CMR.0000000000000453

DO - 10.1097/CMR.0000000000000453

M3 - Article

VL - 28

SP - 326

EP - 332

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 4

ER -